When it comes to combating cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers.
We are focusing on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition. These signaling pathways are abnormal in cancer and promote tumor survival.
With deep expertise, agility and purpose, we are identifying and advancing late-stage, first-in-class clinical assets to market.
117 Kendrick Street Suite 500
Needham, MA 02494